1	Modeling the impact of prioritizing first or second vaccine doses during the 2022 mpox
2	outbreak
3	Authors: Patrick A. Clay ^{1,*} , Emily D. Pollock ¹ , Enrique M. Saldarriaga ¹ , Preeti Pathela ² , Michelle
4	Macaraig ³ , Jane R. Zucker ^{4,5} , Bindy Crouch ⁴ , Ian Kracalik ⁶ , Sevgi O. Aral ¹ , Ian H. Spicknall ¹
5	¹ CDC, National Center for HIV, Hepatitis, STD, and Tuberculosis Prevention, Division of STD
6	Prevention
7	² New York City Department of Health and Mental Hygiene, Bureau of Hepatitis, HIV, and STI
8	³ New York City Department of Health and Mental Hygiene, Bureau of Tuberculosis Control
9	⁴ New York City Department of Health and Mental Hygiene, Bureau of Immunization
10	⁵ CDC, National Center for Influenza and Respiratory Diseases, Immunization Services Division
11	⁶ CDC, National Center for Emerging & Zoonotic Infectious Diseases, Division of High Consequence
12	Pathogens and Pathology
13	*Corresponding author, <u>ruq9@cdc.gov</u> . 1600 Clifton Road, Atlanta, Georgia
14	Word count: 3,476
15	
16	
17	
18	

19

20 Abstract

Background: Early in the 2022 mpox outbreak, vaccine doses and administrative capacity were 21 limited. The US recommendation was to administer two doses of the JYNNEOS® vaccine 4 22 weeks apart. However, because of the limited vaccine supply and high demand, New York City 23 (NYC) prioritized administration of first doses to reach a larger portion of the impacted 24 population as quickly as possible. We estimated mpox cases averted compared to strategies that 25 26 prioritized 2-dose vaccination for a smaller portion of the population. 27 Methods: We fit a dynamic network transmission model to incident mpox cases reported by 28 NYC, as well as to first and second vaccine doses administered from May 2022 through March 29 2023. Model output consisted of predicted cases over time when vaccine doses were administered with the 'first-dose priority' strategy, compared with counterfactual simulations 30 31 where individuals were either pre-allocated full courses of the vaccine ('second-dose priority' strategy), or not pre-allocated doses, but where doses were administered to those eligible for a 32 second dose ahead of those waiting for a first dose ('intermediate' strategy). 33 Results: We estimate that NYC's 'first-dose priority' strategy averted 81% [IQR:75%–86] of 34 potential mpox cases. Their 'first-dose priority' strategy was more effective than alternatives, 35 36 averting 3.0% [IQR:1.2%–4.5%] more cases than the 'intermediate' strategy, and 9.5% [IQR:7.7%–12%] more cases than the 'second-dose priority' strategy. 37 Conclusions: A focus on widespread, 1 dose vaccination during future mpox outbreaks can 38 reduce cases and limit transmission in scenarios of limited vaccine supply, limited vaccine 39

40 administration capacity, or increased demand.

41 Introduction

Over 30,000 individuals in the United States were diagnosed with mpox in 2022, with 42 43 33% of these cases occurring in May through July, and daily cases peaking on August 1st. 44 Official CDC guidance was to administer two doses of the JYNNEOS® vaccine 4 weeks apart to priority populations (primarily gay, bisexual, and other men who have sex with men, hereafter 45 46 referred to as MSM, with multiple recent sexual partners) [1]. During this period of rapidly increasing daily cases, demand for vaccination exceeded available doses of the JYNNEOS® 47 vaccine and the capacity for administration in many jurisdictions. Given the rapidly increasing 48 49 number of cases in New York City (NYC) and the resultant need to protect priority populations as quickly as possible, NYC focused their vaccination campaign on widespread, 1 dose 50 51 vaccination, (a 'first-dose priority' strategy), with plans to administer second doses when supply 52 and demand allowed, rather than following official CDC recommendations, which would have resulted in earlier 2 dose vaccination in a narrower portion of the population. Due to the urgency 53 54 of the outbreak, NYC Health was required to make this decision with limited data on the effectiveness of 2 dose vs. 1 dose vaccination. 55

Understanding the relative impact of prioritizing 2-dose vaccination in a relatively 56 narrow portion of the population (referred to as narrow, 2 dose vaccination) compared to a 'first-57 dose priority' strategy (referred to as widespread, 1 dose vaccination) may inform vaccination 58 59 strategies in potential future mpox outbreaks [2]. We used vaccine administration and case report data from NYC to calibrate a dynamic network model of sexually transmitted monkeypox virus 60 infection among MSM. We then estimated the number of mpox cases averted by vaccine 61 62 administration in NYC over one year. We further estimated the effectiveness of strategies that focused on administering single doses of the vaccine to a widespread portion of the eligible 63

population, as happened in NYC (the "first-dose priority" strategy), compared to an
administration strategy of pre-allocating a full course of doses to a narrow portion of the eligible
population (the "second-dose priority" strategy), as well as a vaccine strategy of not preallocating doses, but choosing to administer vaccines to those eligible for a second dose ahead of
completely unvaccinated individuals (the "intermediate" strategy).

69 Methods

We used a previously described dynamic network model of sexually associated 70 71 monkeypox virus transmission in MSM [2-4], with parameters updated based on nationally distributed surveys of sexual behavior among MSM from 2017-2019 (the ARTnet study) [5]. 72 This model simulates the 167,000 MSM living in NYC, and a changing network of sexual 73 74 partnerships between them. We model three types of sexual partnerships: individuals in our model can have 0 or 1 'Main' partners (defined as enduring sexual partners who took priority 75 over others), between 0 and 3 'Casual partners' (defined as enduring sexual partners besides the 76 77 main partner), and 0 or 1 'one-time' partners per timestep (defined as partners without repeat sexual contact). For each timestep in the model, enduring partnerships have a probability of 78 forming and dissolving, and individuals have a probability of engaging in one-time partnerships 79 based on their assignment to one of 6 sexual activity groups, with activity group 1 representing 80 the lowest sexual activity level (never engaging in one-time partnerships) and activity group 6 81 82 representing the highest sexual activity level (30% chance of engaging in a one-time partnership per day). All network parameters can be found in Table S1. 83

We used an SEIR (susceptible, exposed, infectious, resistant) natural history in our
model, expanded to account for pre-symptomatic transmission and multi-dose vaccination [6].
Individuals start in the susceptible (*S*) class. An infectious individual has a probability of

infecting a susceptible partner given by the probability of sexual contact per timestep multiplied 87 by the probability of infection per sexual exposure (μ). Upon acquiring infection, individuals 88 enter a pre-symptomatic non-infectious state (E), after which they have a probability per day of 89 entering the pre-symptomatic and infectious state (P), then the symptomatic and infectious state 90 91 (I), and finally the recovered and resistant state (R). Individuals can also be vaccinated with 1 92 (V1) or 2 (V2) doses of the vaccine, with effects described below. Symptom onset reduces sexual 93 contact rate with 'main' and 'casual' partners by 50% and causes individuals to move to one lower sexual activity level until they recover. A proportion of individuals, (ρ) , will test for mpox 94 γ days after they develop symptoms, with γ based on the date-varying time between reported 95 96 symptom onset and mpox tests in case data. After a positive mpox test, individuals become aware of their infection status, and no longer transmit the virus through sexual activity. 97 98 Individuals who learn their infection status sustain contact with their 'main' partner such that they have a 10% chance of infecting their 'main' partner over the duration of the infection, 99 reflecting prior estimates of household transmission [7]. Infected individuals who seek medical 100 care are reported as diagnosed cases, hereafter referred to as *cases*. 101 We initiated the model by introducing 5 newly exposed individuals into the two highest 102

sexual activity groups on May 14th. This produced a median of 5 cumulative cases in the model
 on May 31st, matching case data from NYC.

Our network does not account for potential periods of increased sexual activity associated with the high frequency of MSM gatherings (e.g., pride festivals) throughout the summer. Additionally, we assume that importation of mpox cases from countries impacted by mpox prior to the outbreak in the United States may have fed the initial surge of mpox cases. Thus, we model a 'surge period' during which we randomly select individuals in the top two sexual

activity groups to enter the *E* state via 'extra-network' contacts at a rate fit to incident case report data (see fitting procedure below). We set this surge period to occur in the two weeks after NYC Pride (June 26^{th} – July 10^{th}) but note that there were many MSM oriented gatherings in NYC at this time and are not assuming that a disproportionate level of exposures happened at any specific event.

Over the course of each simulation, individuals decrease their probability of one-time partnerships and their rate of sexual contact with casual partners as a function of perceived risk of mpox [8]. We parameterize this perceived risk based on frequency of mpox discussion on online LGBT+ discussion forums over time, as discussed by Clay et al. [4], and fit the magnitude of this behavioral adaptation to incident case report data (see fitting procedure below).

120 Vaccination

We ran three vaccination scenarios (Figure 1). We first ran a scenario where first and 121 122 second doses administered per week matched those reported by NYC through March 18, 2023. This scenario is our baseline 'first-dose priority' strategy, as prioritizing widespread, 1 dose 123 vaccination was the goal of NYC's vaccination campaign. We then ran a counterfactual scenario 124 125 where the total doses administered per week matched those in our 'first-dose priority' strategy, but during each timestep, doses were always administered first to individuals who were due for a 126 127 second dose, and first doses were only given once there were no individuals waiting for a second 128 dose ('intermediate' strategy). Finally, we ran an additional counterfactual scenario where individuals receiving their first dose were pre-allocated a second dose to be administered five 129 weeks later, reflecting average time between doses in other jurisdictions (appendix). Thus, every 130 individual completed their course on time, but total dose administration was slowed ('second-131 132 dose priority' strategy). The cumulative number of cases averted by vaccine administration was

calculated as the cumulative number of cases in the 'no vaccination' scenario minus the
cumulative cases in a scenario with vaccine administration. We compared the number of cases
averted by the baseline scenario to the number of cases averted by the counterfactual vaccination
scenarios.

While MSM, transgender, gender non-conforming and non-binary adults (TGNCNB)
with multiple sexual partners were all initially eligible for mpox vaccination, we only model
MSM due to availability of sexual network data [5]. According to a 2020 citywide populationbased survey, MSM made up 82% of MSM and TGNCNB adults in NYC with 2+ sexual
partners over a 12-month period [9]. Thus, we assume that 82% of mpox vaccines administered
in NYC were administered to MSM in our model.

143 As vaccines were originally intended for selected groups, including individuals with multiple recent sexual partners [10], we only vaccinate individuals in the top two sexual activity 144 groups for the first four weeks of vaccination, only vaccinate individuals in the top four sexual 145 activity groups for the next four weeks of vaccination, and only vaccinate individuals with a non-146 zero probability of engaging in one-time sexual partnerships for the rest of the simulation. In our 147 148 model, susceptible (S) and pre-symptomatic (E, P) individuals are eligible for vaccination. However, vaccination does not prevent individuals in the *E* or *P* class from becoming infectious. 149 150 Individuals are eligible for second doses of the vaccine if they have received their first dose at 151 least four weeks in the past. In the case of breakthrough infections (i.e. infections of vaccinated individuals), we assume these individuals enter the pre-symptomatic (E) class, i.e., prior 152 vaccination has no effects on subsequent contagiousness or pathogenicity. 153

154 CDC recently published JYNNEOS® effectiveness estimates (the overall reduction in
 155 infection risk for a vaccinated individual compared to an unvaccinated individual over an

observed period) of 75.2% for one dose, and 85.9% for two doses [11]. We use these values in 156 our model as per-exposure reductions in transmission probability due to vaccination, hereafter 157 referred to as per-exposure vaccine efficacy. Setting vaccine effectiveness equal to per-exposure 158 vaccine efficacy requires the assumption that individuals in the vaccine effectiveness study were 159 not exposed to mpox multiple times (Figure S2). If individuals in the vaccine effectiveness study 160 161 were exposed to mpox multiple times, we would expect for per-exposure vaccine efficacy to be 162 greater than vaccine effectiveness. We thus repeated our analysis while increasing per-exposure 163 vaccine efficacy by 10% and found no qualitative difference in our results (Figures S4-6). In all 164 scenarios, we assume that doses become effective two weeks after administration.

165 Fitting Process

Our model has three free parameters whose values were informed via fitting: (1) the
probability of transmission per exposure ('transmission probability', μ), (2) the number of
additional individuals infected per day by extra-network contacts during the 'surge period'
('surge exposures', ε), and (3) the maximum percent reduction in probability of one-time or
casual sexual contact per day in response to perceived risk of mpox ('behavioral adaptation', ω).
We fit these parameters to incident daily cases in NYC using a 5-step process.

First, we used Latin Hypercube Sampling (LHS) to generate 1,000 unique parameter sets, sampling between 40% and 100% transmission probability, between 100 and 1,000 surge exposures, and between 0% and 60% behavioral adaptation. Prior studies used transmission probability values below our minimum [12], but these lower values were based off estimates of household, rather than sexual, transmission, and do not generate sustained transmission in our network.

178	Second, we simulated a single run of outbreak dynamics under the baseline 'first-dose
179	priority' strategy employed by NYC for each LHS-generated parameter set from May 14, 2022
180	to January 18, 2023 (250 simulated days). Third, we filtered out parameter sets which predicted a
181	final cumulative case incidence outside of that observed in NYC +/- 50% . Fourth, for each
182	remaining parameter set, we calculated the likelihood that the simulated number of incident daily
183	cases could generate the observed number of incident daily cases through Jan 18 using a negative
184	binomial probability distribution. Finally, we drew 100 parameter sets (with replacement) with
185	the calculated likelihood used as the relative draw probability for each parameter set. These 100
186	drawn parameter sets represent the posterior distributions of our fit parameters.
187	For each of these 100 parameter sets, we ran each of our vaccine model scenarios (Figure
188	1) from May 14, 2022 to May 14, 2023 and compared median and interquartile ranges of
189	cumulative cases over time for each vaccine administration strategy. We additionally ran a third
190	counterfactual model scenario where no vaccines were administered to measure the total percent
191	of cases averted by vaccination compared to the 'first-dose priority' strategy (baseline model).
192	Results
193	Our fitting procedure selected for a transmission probability of 59% [IQR: 55% – 65%],
194	440 surge exposures [IQR: 280 – 560], and behavioral adaptation of 37% [IQR: 26% – 47%]
195	(Figure 2, Table 2). The posteriors of transmission probability and behavioral adaptation are both
196	correlated with surge exposures (Figure S3). Thus, these parameter estimates should not be used
197	in other contexts.

Our model estimates that there would have been 17,800 cumulative cases [IQR: 13,000 –
25,900] by May 14, 2023 in the counterfactual scenario with no vaccination. Our model further

estimates that the baseline 'first-dose priority' strategy averted 81% [IQR: 75% – 86%] of these
cases (Figure 3).

202 Taking the difference in cases averted across all parameter sets, we estimate that 203 compared to the baseline 'first-dose priority' strategy employed by NYC, the counterfactual 'intermediate' strategy would have averted 3.0% [IQR: 1.2% - 4.5%] fewer cases, and the 204 205 counterfactual 'second-dose priority' strategy would have averted 9.5% [IQR: 7.7% – 12%] fewer cases (Figure 4A). This would result in up to 2,000 fewer cases averted had NYC chosen 206 207 an alternative vaccine administration strategy. This result is driven by exposure heterogeneity 208 and incremental dose efficacy. In our model, the first individuals vaccinated have a one-time partner acquisition rate 250 times greater than individuals vaccinated later in the outbreak (Table 209 S1), which favors narrow, 2 dose vaccination of individuals with higher sexual activity. 210 However, this exposure heterogeneity is overwhelmed by the second vaccine dose adding 211 relatively little incremental protection (10.7%) compared to the first dose (75.2%), which favors 212 widespread, 1 dose vaccination. 213

NYC was allocated a relatively high number of JYNNEOS doses per high priority 214 individual compared to many other jurisdictions. Thus, we conducted additional analyses, 215 reducing doses administered in the NYC model by 75% to estimate whether the optimal vaccine 216 administration strategy would differ if NYC had been allocated fewer doses. We found that in 217 218 this scenario, the baseline 'first-dose priority' strategy was even more superior, averting 43% [IQR: 39% – 48%] of cases, while the counterfactual 'intermediate' strategy averted 11% [IQR: 219 220 2.0% - 18%] fewer cases, and the counterfactual 'second-dose priority' strategy averted 25% 221 [IQR: 13% – 34%] fewer cases than the 'first-dose priority' strategy (Figure 4B).

222	In addition to incremental dose efficacy and heterogeneity in exposure probabilities, the
223	overall transmissibility of a pathogen will influence whether widespread, 1 dose vaccination or
224	narrow, 2 dose vaccination is favored. When we increase per-exposure vaccine efficacy
225	(appendix S.5), our fitting procedure selected parameter sets with higher monkeypox virus
226	transmissibility, increasing cumulative cases in the no-vaccine scenario by 8.2% (Figure 2 vs.
227	Figure S5). Because most transmission events in our model happen among high-activity
228	individuals, in this higher transmissibility scenario, high activity individuals may need more per-
229	exposure protection to reduce the effective growth rate of mpox to below 1. This favors narrow,
230	2 dose vaccination strategies more than our primary analysis (Figure 2), resulting in all vaccine
231	administration strategies averting similar numbers of cases (Figure S6).

232 Discussion

During the 2022 mpox outbreak, demand for vaccines initially outstripped supply, 233 234 preventing 2 dose vaccination for the total population likely to benefit from vaccination. Thus, NYC prioritized administration of first doses to reach a larger portion of the impacted population 235 as quickly as possible. In this analysis, we modeled the strategy focusing on widespread, 1 dose 236 237 vaccination employed by NYC, compared to counterfactual strategies focusing on 2 dose vaccination in narrower portions of the population. We estimated that the NYC vaccine rollout 238 prevented 81% of potential mpox cases. We further estimated that NYC's strategy of prioritizing 239 240 widespread, 1 dose vaccination (the 'first-dose priority' strategy) averted more cases than alternative strategies prioritizing narrow, 2 dose vaccination, and would also have been the 241 242 superior strategy had vaccine supply been even more limited.

Increasing vaccine coverage will decrease the probability of future mpox outbreaks and
decrease the size of outbreaks if they occur [2]. CDC estimates that a vaccination threshold of

50% among priority populations (HIV PrEP indicated MSM and MSM living with HIV) would 245 prevent monkeypox virus transmission [2]. However, 70% of analyzed jurisdictions, including 246 247 urban centers with large MSM populations, are currently below this thresholds, with 34% of analyzed jurisdictions having vaccinated 25% or less of the priority population [2]. Thus, CDC 248 recommends the continued vaccination of priority populations to prevent future mpox outbreaks 249 250 [13]. Currently, vaccine availability outstrips demand among priority populations, and state and 251 local health departments do not need to decide whether to prioritize narrow, 2 dose vaccination 252 or widespread, 1 dose vaccination. Rather, state and local health departments can focus both on 253 initiating the vaccine series for those in priority population who remain unvaccinated or have recently entered the priority population, followed by completion of the 2 dose vaccine series. 254 Completing the vaccine series is important as the duration of effectiveness of a single dose is not 255 256 known.

Given the potential for mpox resurgence as well as for mpox to spread to populations not 257 258 previously impacted by mpox, demand for mpox vaccines could increase, potentially exceeding 259 vaccine supply or vaccination capacity. In either situation, local and state health departments 260 may consider whether to focus on prioritizing narrow, 2 dose vaccination, or widespread, 1 dose 261 vaccination. Our analysis shows that in NYC, prioritizing widespread, 1 dose vaccination averted 262 the greatest number of cases, making it the superior strategy, though it may be equivalent to 263 other strategies if we are underestimating per-exposure vaccine efficacy. Even if all strategies 264 were equivalent in averting cases, prioritizing widespread, 1 dose vaccination has the benefit of 265 improving vaccine equity. In recent vaccine rollouts, groups who have historically faced systematic barriers to accessing healthcare received a disproportionally small number of initial 266 vaccine doses [14]. Narrow, 2 dose vaccination strategies, which focus on concentrating all 267

vaccine doses in a smaller number of individuals who access vaccine doses first, may thus 268 exacerbate health inequities. This is particularly problematic as individuals are most likely to 269 270 have close sexual contact with individuals of the same race or socioeconomic status [15]. Narrow, 2 dose strategies may thus lead to uncontrolled transmission in groups already facing a 271 disproportionate burden of most health problems, exacerbating health disparities. 272 273 Vaccination can yield greater health benefits when the selection of vaccine administration 274 strategies takes into account heterogeneity in immune function, which may in turn generate 275 heterogeneity in both individual susceptibility and vaccine effectiveness. People with HIV 276 (PWH) make up 19% of MSM [16,17], but 55% of mpox cases in the United States with known 277 and recorded HIV status. The disproportionate representation of PWH among mpox cases may 278 be caused by (a) PWH having a higher probability of mpox exposure, (b) PWH having a greater susceptibility to monkeypox virus infection, or (c) PWH being more likely to experience mpox 279 symptoms when infected, given that coinfection between HIV and mpox can lead to severe, life-280 281 threatening outcomes in individuals not receiving antiretroviral therapy and who had low CD4 counts [18]. JYNNEOS® vaccination has reduced efficacy in individuals living with 282 283 immunocompromising conditions, including uncontrolled HIV, with a reduction in first-dose 284 effectiveness of 21.1%, and a reduction of second-dose effectiveness of 17.6%. Further, the

incremental effectiveness of second dose vaccination is higher in people living with

immunocompromising conditions than in others, with second dose vaccination increasing

effectiveness by 20.8 percentage points, compared to 10.7 percentage points. Thus, because
PWH may be more likely to acquire mpox, are more likely to experience severe symptoms, and
benefit more from receiving a second vaccine dose than others, future vaccination strategies may
benefit from giving PWH 2 dose vaccine courses as quickly as possible, even if the larger

vaccine strategy is for widespread, 1 dose vaccination. This strategy could be paired with further
efforts to connect people living with uncontrolled HIV to HIV services, given that increased
CD4 counts may increase vaccine efficacy and reduce severity of mpox.

294 Choosing whether to prioritize completion of a multi-dose course in a narrow portion of the population at high likelihood of infection, versus widespread, 1 dose vaccination will arise in 295 296 future outbreaks of other diseases, whenever vaccination involves multiple doses [19]. When choosing between vaccination strategies during an outbreak, public health agencies need to be 297 quick, flexible, and make decisions with limited data. Mathematical modelers can conduct 298 299 studies now, before those outbreaks occur, that will allow public health officials to make informed decisions during the initial stages of an outbreak. The optimal vaccine strategy in an 300 outbreak will depend on multiple factors, including the incremental effectiveness of first vs. 301 second doses, the population contact network, vaccine administration capacity, and the epidemic 302 303 growth rate. Modeling studies can explore how these parameters shift the optimal vaccination 304 strategy, while connecting these parameters to pre-existing data (e.g., the population contact network), or data that can be easily collected in the early stages of an outbreak (e.g. epidemic 305 306 growth rate). Results from these studies can inform decisions for public health officials, leading 307 to quick, evidence-based public health leadership.

308 Acknowledgments

The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention or the National Cancer Institute. We would like to thank Dr. Jennifer Rosen for her support.

312 Data Availability

313 Data and code available upon reasonable request to authors.

314

315 **Bibliography**

- 1. JYNNEOS Vaccine | Mpox | Poxvirus | CDC [Internet]. [cited 2023 May 17]. Available
- 317 from: https://www.cdc.gov/poxvirus/mpox/interim-considerations/jynneos-vaccine.html
- 2. Pollock ED, Clay PA, Keen A, et al. Potential for Recurrent Mpox Outbreaks Among
- Gay, Bisexual, and Other Men Who Have Sex with Men United States, 2023. MMWR
- 320 Morb Mortal Wkly Rep [Internet]. **2023** [cited 2023 May 26]; 72(21):568–573. Available
- 321 from: https://www.cdc.gov/mmwr/volumes/72/wr/mm7221a1.htm
- 322 3. Spicknall IH, Pollock ED, Clay PA, et al. Modeling the impact of sexual networks in the
- transmission of Monkeypox virus among gay, bisexual, and other men who have sex with
- men United States, 2022 [Internet]. 2022 [cited 2022 Oct 25]. Available from:
- 325 https://stacks.cdc.gov/view/cdc/120698
- 4. Clay PA, Asher JM, Carnes N, et al. Modelling the impact of vaccination and sexual
- behavior change on reported cases of mpox in Washington D.C. medRxiv [Internet]. Cold
- Spring Harbor Laboratory Press; **2023** [cited 2023 May 17]; :2023.02.10.23285772.
- 329 Available from: https://www.medrxiv.org/content/10.1101/2023.02.10.23285772v1
- Weiss KM, Goodreau SM, Morris M, et al. Egocentric sexual networks of men who have
 sex with men in the United States: Results from the ARTnet study. Epidemics. Elsevier;
 2020; 30:100386.
- Brosius I, Dijck C Van, Coppens J, et al. Presymptomatic viral shedding in high-risk

334		mpox contacts: A prospective cohort study. J Med Virol [Internet]. John Wiley & Sons,
335		Ltd; 2023 [cited 2023 May 17]; 95(5):e28769. Available from:
336		https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.28769
337	7.	Beer EM, Bhargavi Rao V. A systematic review of the epidemiology of human
338		monkeypox outbreaks and implications for outbreak strategy. PLoS Negl Trop Dis
339		[Internet]. Public Library of Science; 2019 [cited 2023 Jan 27]; 13(10):e0007791.
340		Available from:
341		https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0007791
342	8.	Delaney KP, Sanchez T, Hannah M, et al. Strategies Adopted by Gay, Bisexual, and Other
343		Men Who Have Sex with Men to Prevent Monkeypox virus Transmission — United
344		States, August 2022. MMWR Morb Mortal Wkly Rep [Internet]. Centers for Disease
345		Control MMWR Office; 2022 [cited 2022 Oct 25]; 71(35). Available from:
346		https://www.cdc.gov/mmwr/volumes/71/wr/mm7135e1.htm
347	9.	New York City Department of Health and Mental Hygeine. EpiQuery - Community
348		Health Survey 2020 [Internet]. [cited 2023 Aug 4]. Available from: https://a816-
349		health.nyc.gov/hdi/epiquery/visualizations?PageType=ps&PopulationSource=CHS
350	10.	FACT SHEET: Biden-Harris Administration's Monkeypox Outbreak Response The
351		White House [Internet]. [cited 2022 Nov 1]. Available from:
352		https://www.whitehouse.gov/briefing-room/statements-releases/2022/06/28/fact-sheet-
353		biden-harris-administrations-monkeypox-outbreak-response/
354	11.	Dalton AF, Diallo AO, Chard AN, et al. Estimated Effectiveness of JYNNEOS Vaccine in
355		Preventing Mpox: A Multijurisdictional Case-Control Study — United States, August 19,

356 2022–March 31, 2023. MMWR Morb Mortal Wkly Rep [Internet]. **2023** [cited 2023 May

- 357 23]; 72(20):553–558. Available from:
- 358 https://www.cdc.gov/mmwr/volumes/72/wr/mm7220a3.htm
- 12. Endo A, Murayama H, Abbott S, et al. Heavy-tailed sexual contact networks and
- 360 monkeypox epidemiology in the global outbreak, 2022. Science (80-) [Internet].
- 361 American Association for the Advancement of Science; **2022** [cited 2023 Jan 27];
- 362 378(6615). Available from: https://www.science.org/doi/10.1126/science.add4507
- 13. Vaccination | Mpox | Poxvirus | CDC [Internet]. [cited 2023 May 26]. Available from:
- 364 https://www.cdc.gov/poxvirus/mpox/interim-considerations/overview.html
- 14. Baack BN, Abad N, Yankey D, et al. COVID-19 Vaccination Coverage and Intent Among
- Adults Aged 18–39 Years United States, March–May 2021. Morb Mortal Wkly Rep
- 367 [Internet]. Centers for Disease Control and Prevention; **2021** [cited 2023 May 26];
- 368 70(25):928. Available from: /pmc/articles/PMC8224866/
- 15. Hernández-Romieu AC, Sullivan PS, Rothenberg R, et al. Heterogeneity of HIV
- prevalence among the sexual networks of Black and White MSM in Atlanta: illuminating
- a mechanism for increased HIV risk for young Black MSM. Sex Transm Dis [Internet].
- 372 NIH Public Access; **2015** [cited 2022 Oct 26]; 42(9):505. Available from:
- 373 /pmc/articles/PMC4536576/
- 16. Linley L, Johnson AS, Song R, et al. Estimated HIV incidence and prevalence in the
- United States 2010–2019 [Internet]. 2021 [cited 2023 May 18]. Available from:
- 376 https://stacks.cdc.gov/view/cdc/112160
- 17. Grey JA, Bernstein KT, Sullivan PS, et al. Estimating the Population Sizes of Men Who

- Have Sex With Men in US States and Counties Using Data From the American
- Community Survey. JMIR Public Heal Surveill 2016;2(1)e14
- 380 https//publichealth.jmir.org/2016/1/e14 [Internet]. JMIR Public Health and Surveillance;
- **2016** [cited 2022 Oct 31]; 2(1):e5365. Available from:
- 382 https://publichealth.jmir.org/2016/1/e14
- 18. Mitjà O, Alemany A, Marks M, et al. Mpox in people with advanced HIV infection: a
- 384 global case series. Lancet. Elsevier; **2023**; 401(10380):939–949.
- 19. Adult Immunization Schedule Healthcare Providers | CDC [Internet]. [cited 2023 May
- 386 19]. Available from: https://www.cdc.gov/vaccines/schedules/hcp/imz/adult.html
- 20. Aral SO, Blanchard JF. The Program Science initiative: improving the planning,
- implementation and evaluation of HIV/STI prevention programs. Sex Transm Infect
- 389 [Internet]. BMJ Publishing Group Ltd; **2012** [cited 2023 Aug 1]; 88(3):157–159.
- 390 Available from: https://sti.bmj.com/content/88/3/157
- 21. Charniga K, Masters NB, Slayton RB, et al. Estimating the incubation period of
- monkeypox virus during the 2022 multi-national outbreak. medRxiv [Internet]. Cold
- Spring Harbor Laboratory Press; **2022** [cited 2023 May 17]; :2022.06.22.22276713.
- 394 Available from: https://www.medrxiv.org/content/10.1101/2022.06.22.22276713v2
- Farley TA, Cohen DA, Elkins W. Asymptomatic sexually transmitted diseases: the case
 for screening. Prev Med (Baltim). Academic Press; 2003; 36(4):502–509.
- 397 23. Jenness SM, Weiss KM, Goodreau SM, et al. Incidence of Gonorrhea and Chlamydia
- 398 Following Human Immunodeficiency Virus Preexposure Prophylaxis Among Men Who
- Have Sex With Men: A Modeling Study. Clin Infect Dis [Internet]. Oxford Academic;

400 **2017** [cited 2023 Feb 16]; 65(5):712–718. Available from:

401 https://academic.oup.com/cid/article/65/5/712/3824878

402 Table 1: Model parameters. Values given as a range represent priors of parameters fit to data.

Parameter Description	Value	Source		
Initial Conditions				
Population size	167,000	EpiQuery - Community		
		Health Survey 2020: NYC		
		Department of Health and		
		Mental Hygeine.		
Initial number infectious	5	Model Assumption		
individuals				
Date seeded with initial	May 14 th	Selected to align date of 5		
infections		cases in median model output		
		and case reports		
Surge Exposures (Number	[100 - 1000]	Fit to case report data		
individuals infected from				
June 26 – July 10, a period of				
large gatherings of gay,				
bisexual, and other men who				
have sex with men)				
Natural History Parameters	·	·		

Transmission Probability	[40% - 100%]	Fit to case report data
(Probability of transmission		
per sexual contact)		
Mean duration of post-	7.6 days	Charniga K, Masters NB,
exposure, pre-symptomatic		Slayton RB, et al. Estimating
period		the incubation period of
		monkeypox virus during the
		2022 multi-national outbreak.
		medRxiv. 2022
Mean duration of pre-	4 days	Brosius I, Dijck C Van,
symptomatic infectious		Coppens J, et al.
period		Presymptomatic viral
		shedding in high-risk mpox
		contacts: A prospective
		cohort study. J Med Virol
		[Internet]. 2023
Mean duration of infectious	27 days	Spicknall IH, Pollock ED,
period		Clay PA, et al. Modeling the
		impact of sexual networks in
		the transmission of
		Monkeypox virus among gay,
		bisexual, and other men who

		have sex with men — United
		States, 2022. MMWR. 2022
Treatment Seeking and Vaccin	e Parameters	
Probability of seeking	0.8	Farley TA, Cohen DA, Elkins
treatment		W. Asymptomatic sexually
		transmitted diseases: the case
		for screening. Prev Med.
		2003
Duration of infectious period	15 days on first day of	Case Report Data
if seeking treatment (time	simulation, linearly decreases	
until medical attention post-	to 5.0 days on day 42 of	
symptoms)	simulation, stays at 5.0 days	
	for rest of simulation.	
First dose per-exposure	75.2% (85% in sensitivity	Dalton AF, Diallo AO, Chard
vaccine efficacy	analysis)	AN, et al. Estimated
Second dose per-exposure	85.9% (95% in sensitivity	Effectiveness of JYNNEOS
vaccine efficacy	analysis)	Vaccine in Preventing Mpox:
		A Multijurisdictional Case-
		Control Study — United
		States, August 19, 2022–
		March 31, 2023. MMWR.
		2023

Minimum time between first	28 days	JYNNEOS Vaccine Mpox		
and second dose		Poxvirus CDC [Internet].		
Behavior Change Parameters				
Behavioral Adaptation	[0% - 60%]	Fit to case report data		
(Maximum percent reduction				
in daily probability of				
forming one-time sexual				
partnerships.)				

403

404 Table 2: Posterior values of parameters fit to incident cases.

Parameter	Median	1 st quartile	3 rd Quartile
Surge Exposures (Number	440	280	560
individuals infected from			
June 26 – July 10, a period of			
large gatherings of gay,			
bisexual, and men who have			
sex with men)			
Transmission Probability	59%	55%	65%
(Probability of transmission			
per sexual contact)			
Behavioral Adaptation	37%	26%	47%
(Maximum percent reduction			

in daily probability of		
forming one-time sexual		
partnerships.)		



406

Figure 1: Allocation of doses over time for each vaccine administration strategy*. Y-axis shows number
of doses given over time on the X-axis. Top two panels indicate number of first and second doses given,
respectively, for each vaccine administration strategy while bottom panel indicates the sum of first and
second doses given for each vaccine administration strategy. Colors indicate different vaccine
administration strategies.

- 412 *First-dose priority: first and second doses in model are based on first and second doses administered by
- 413 NYC. Intermediate: Individuals who are eligible for a second dose receive priority for available doses, but
- there is no preallocation. Second-dose priority: doses are preallocated to ensure that all individuals
- 415 receive full course of thes vaccine.



Figure 2: Mpox model fit to data. Dots indicate the 1 week running mean of incident daily cases in NYC, used as our fitting target. Blue line in represents median incident daily cases of model runs from the 100 parameter sets selected in our fitting procedure, with band representing interquartile range of model runs, assuming a 'first-dose priority' strategy. Labels indicate the beginning of pre-exposure vaccination on June 26th, peak administration of first doses, occurring the week of August 7th, and peak administration of second doses, occurring the week of September 18th.



423

Figure 3: Estimated cumulative cases over a year under the 'first-dose priority' strategy employed by
NYC compared to a 'no vaccination' scenario. Lines represent median cumulative cases of model runs
from the 100 parameter sets selected in our fitting procedure, with bands representing interquartile ranges
of model runs.





Figure 4: Comparison of different vaccine administration strategies^{*}. We show the difference in cases under the 'intermediate' or 'second-dose priority' strategy compared to the 'first-dose priority' strategy on the Y-axis, over time on the X-axis. Solid lines indicate median values across fit parameter sets, and transparent bands indicate interquartile ranges across parameter sets. Panel A uses vaccine administration numbers shown in Figure 1, while panel B cuts doses given by 75% to emulate jurisdictions with lower dose availability.

*First-dose priority: first and second doses in model are based on first and second doses administered by
NYC. Intermediate: Individuals who are eligible for a second dose receive priority for available doses, but
there is no preallocation. Second-dose priority: doses are preallocated to ensure that all individuals
receive full course of thes vaccine.